Core Sound Imaging Announces Studycast & Us2.ai Partner Integration

Core Sound Imaging and Us2.ai finalize integration agreement. Us2.ai joins Studycast Integration Program, bringing AI-automated Echocardiography analysis and decision support tools  into clients’ imaging and reporting solution. Us2.ai is an FDA cleared app that reports on heart structure and function, with fully automated analyses of ALL heart chambers using both 2D and Doppler views, rendering a … Read more

Epigenetics Market size to grow by USD 1,148.2 million from 2022-2027 with 40% of the market growth originate from North America

NEW YORK, June 16, 2023 /PRNewswire/ — The epigenetics market size is expected to grow by USD 1,148.2 million during 2022-2027, progressing at a CAGR of 14.06% as per the latest Technavio market research report. North America is going to have lucrative growth during the forecast period. North America is estimated to contribute 40% of the global market during the forecast period. Technavio’s … Read more

Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

DUBLIN, June 16, 2023 /PRNewswire/ — The “Dental 3D Printing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028” report has been added to ResearchAndMarkets.com’s offering. The global dental 3D printing market size reached US$ 2.6 Billion in 2022. Looking forward, the publisher expects the market to reach US$ 5.6 Billion by 2028, exhibiting a CAGR … Read more

Soon a saliva test to diagnose endometriosis?

Currently, it is a laparoscopy that makes it possible to make the diagnosis of endometriosis. The effectiveness of a simple saliva test, developed by a French start-up, has however just been demonstrated in a study. In patients who suffer from endometriosis, the diagnostic delay can last 8 years on average. If it keeps its promises, … Read more

TG ImmunoPharma Announces FDA Clearance for Clinical Trial of TGI-6 Bispecific Antibody

HEFEI, China, June 16, 2023 /PRNewswire/ — TG ImmunoPharma Co., Ltd. (TGI), a leading biotech company focused on the development of novel immuno-oncology therapies, is pleased to announce that the FDA has granted clearance for the clinical trial of TGI-6, its groundbreaking bispecific antibody. TGI-6 targets unique tumor-associated antigens (TAA) and CD3 molecules simultaneously, enabling … Read more